Drug DevelopmentZentalis' Zn-c3 faces toxicity issues due to off-target PLK activity, necessitating intermittent dosing which is less ideal than continuous dosing.
Industry CompetitionCompeting molecules from Repare, AstraZeneca, and Bayer have faced toxicity issues, particularly with anemia, potentially limiting their therapeutic use.
Stock StructureCompany completed 1:20 reverse split, typically a move made by companies facing stock price pressures or to maintain compliance with exchange listing requirements.